Phospho-BRAF (T599) Antibody

Basic Research Questions

• What is the biological significance of BRAF T599 phosphorylation?

Phosphorylation at threonine 599 (T599) plays a critical role in BRAF activation and function within the MAPK signaling pathway. The T599 site is part of the evolutionary conserved TVKS-motif (T599, V600, K601, S602) in the activation loop (AL) of BRAF. When T599 and S602 become phosphorylated, they induce conformational changes in the kinase domain that lead to several important structural and functional consequences:

• Alignment of the C- and R-spine residues

• Enhanced ATP uptake

• Increased MEK phosphorylation capability

• Exposure of the dimer interface (DIF), which is essential for allosteric activation

These changes collectively transform BRAF from an inactive to an active state, enabling it to phosphorylate downstream targets like MEK and subsequently activate the ERK pathway. The significance of this phosphorylation is highlighted by experiments showing that alanine substitution (AVKA) of T599/S602 impairs Ras-induced activity, while phosphomimetic substitutions (EVKD) confer transforming properties to BRAF .

• How do I optimize immunohistochemistry protocols for phospho-BRAF (T599) antibodies?

Successful immunohistochemical detection of phosphorylated BRAF (T599) requires careful optimization:

Sample preparation:

• Use formalin/PFA-fixed paraffin-embedded sections

• Follow manufacturer's recommended antigen retrieval methods (typically heat-induced epitope retrieval in citrate buffer pH 6.0)

Antibody dilution:

• Start with the manufacturer's recommended dilution range (typically 1:50-1:100)

• Perform a dilution series to determine optimal concentration

Validation controls:

• Include a positive control (e.g., breast cancer tissue known to express phospho-BRAF)

• Use a blocking peptide control to confirm specificity, comparing staining with and without the presence of a blocking peptide

Signal detection:

• Use a detection system appropriate for rabbit primary antibodies

• Consider signal amplification for low-expressing samples

For troubleshooting, if background staining occurs, increase antibody dilution or include additional blocking steps. If signal is weak, extend primary antibody incubation time or optimize antigen retrieval conditions .

• What are the key differences between BRAF T599 phosphorylation and BRAF V600E mutation?

While both T599 phosphorylation and V600E mutation lead to BRAF activation, they represent distinct regulatory mechanisms:

• How do I select the appropriate applications for phospho-BRAF (T599) antibodies in my research?

Selection of appropriate applications should be based on research objectives and available samples:

For protein expression/activation studies:

• Western blot (WB): Use for quantitative assessment of phospho-BRAF levels in cell or tissue lysates (typical dilution 1:500-2000)

• ELISA: Useful for high-throughput screening or monitoring phosphorylation in large sample sets (typical dilution 1:40000)

For localization/tissue studies:

• Immunohistochemistry (IHC): Best for examining phospho-BRAF in tissue context, especially in clinical samples (typical dilution 1:50-1:300)

• Immunofluorescence (IF): Provides better resolution and co-localization capabilities (typical dilution 1:50-200)

Application selection considerations:

• Tissue fixation method (phospho-epitopes can be sensitive to fixation)

• Required sensitivity (IF and ELISA typically provide higher sensitivity)

• Need for spatial information (IHC/IF) versus quantitative data (WB/ELISA)

• Antibody validation status for specific applications

Most commercial phospho-BRAF (T599) antibodies have been validated for multiple applications, but performance may vary between vendors . Always validate antibody performance in your specific experimental system before proceeding with full-scale experiments.

• What controls should I include when using phospho-BRAF (T599) antibodies?

Proper controls are essential for ensuring reliable and interpretable results:

Positive controls:

• Cell lines with activated BRAF signaling (e.g., cells treated with EGF)

• Known positive tissues (e.g., breast cancer tissue has been validated)

• Recombinant phosphorylated BRAF protein (if available)

Negative controls:

• Samples treated with phosphatase to remove phosphorylation

• Samples from BRAF-knockout or BRAF-low expression models

• Primary antibody omission control

Specificity controls:

• Blocking peptide competition assay - preincubation of antibody with the immunizing phosphopeptide should abolish specific staining

• Comparison with total BRAF antibody staining pattern

• Validation in cells expressing BRAF T599A mutant (cannot be phosphorylated at this site)

Technical controls:

• Isotype control antibody (same species and isotype as phospho-BRAF antibody)

• Secondary antibody-only control to assess non-specific binding

Advanced Research Questions

• How does the dimer interface mutation R509H differentially affect wild-type BRAF versus oncogenic BRAF signaling in relation to T599 phosphorylation?

The R509H mutation in the dimer interface (DIF) has revealed important differences in how wild-type and oncogenic BRAF variants utilize dimerization for signaling:

Effect on wild-type BRAF:

• R509H mutation reduces cellular MEK phosphorylation potential of wild-type BRAF by >60%

• When combined with additional mutations L515G and M517W (3x mutation), signaling is reduced by >90%

• This indicates wild-type BRAF strongly depends on dimer formation for effective signaling

Effect on oncogenic BRAF variants:

• BRAF V600E oncoprotein is only slightly affected by R509H mutation

• Even with the 3x mutation, BRAF V600E retains >50% of its activity

• BRAF G469A (P-loop mutant) signaling is reduced by <40% with R509H

• BRAF insT (T599 duplication) shows similar resilience to DIF disruption

These findings demonstrate that oncogenic BRAF mutations, especially V600E, render the kinase significantly less dependent on dimerization for signaling compared to wild-type BRAF. This has important implications for therapeutic approaches targeting the dimer interface, as they may be less effective against tumors driven by BRAF V600E and other high-activity mutants.

Molecular mechanism:
The differential effect likely relates to how T599 phosphorylation occurs in wild-type versus mutant contexts. In wild-type BRAF, T599 phosphorylation often occurs in trans within a dimer, while V600E mutation mimics the phosphorylated state and reduces dependence on this trans-phosphorylation mechanism .

• What techniques can be employed to study the dynamics of T599 phosphorylation in living cells?

Investigating the spatiotemporal dynamics of BRAF T599 phosphorylation in living cells requires sophisticated techniques:

Fluorescence-based approaches:

• FRET biosensors: Design sensors with phospho-binding domains that change conformation upon T599 phosphorylation

• Split fluorescent protein complementation: Tag BRAF and phospho-binding domains with complementary fragments that fluoresce when brought together by phosphorylation

• Phospho-specific antibody fragments conjugated to quantum dots for live-cell imaging

Mass spectrometry approaches:

• SILAC labeling combined with immunoprecipitation to quantify changes in T599 phosphorylation under various conditions

• Multi-protease digestion approach for improved sequence coverage around the T599 site

• Phosphoproteomics with TiO₂ enrichment to enrich phosphopeptides containing T599

Genetic approaches:

• CRISPR-Cas9 knock-in of fluorescently tagged BRAF with phosphomimetic or non-phosphorylatable mutations at T599

• Optogenetic systems to induce BRAF dimerization and monitor subsequent T599 phosphorylation

Experimental setup for dynamics studies:

• Establish cell lines with appropriate reporters

• Apply stimuli that induce BRAF activation (e.g., growth factors, oncogenic RAS expression)

• Monitor phosphorylation in real-time using confocal or TIRF microscopy

• Analyze data using advanced image analysis algorithms to quantify phosphorylation kinetics

These approaches can reveal how T599 phosphorylation correlates with BRAF dimer formation, subcellular localization, and activation of downstream signaling cascades in different cellular contexts .

• How do BRAF inhibitors affect T599 phosphorylation status, and what are the implications for resistance mechanisms?

BRAF inhibitors have complex effects on T599 phosphorylation that contribute to both therapeutic efficacy and resistance mechanisms:

Type I BRAF inhibitors (e.g., vemurafenib, dabrafenib):

• In BRAF V600E mutant cells:

  • Directly inhibit kinase activity

  • Reduce T599 phosphorylation as part of pathway inhibition

  • Resistance often involves reactivation of the pathway via various mechanisms

• In wild-type BRAF cells with active RAS:

  • Induce paradoxical activation

  • Promote BRAF dimerization

  • Increase trans-phosphorylation at T599

  • Lead to enhanced MAPK pathway activation

Type II BRAF inhibitors (e.g., sorafenib):

• Induce conformational changes in BRAF protein

• Promote BRAF dimerization

• Increase phosphorylation of sites including the T401 cluster, which occurs in trans within a Raf dimer

• Create distinct phosphorylation patterns compared to RAS activation

Implications for resistance:
Monitoring T599 phosphorylation status can serve as a biomarker for:

• Effective BRAF inhibition in V600E mutant tumors

• Paradoxical activation in wild-type BRAF cells

• Development of resistance mechanisms involving BRAF reactivation

Studies have shown that vemurafenib-sensitive phosphorylation of other regulatory sites (e.g., T401 cluster) occurs in trans within RAF dimers, suggesting that combination approaches targeting both the catalytic site and dimer interface might overcome certain resistance mechanisms .

• What is the relationship between BRAF T599 phosphorylation and novel regulatory phosphorylation clusters?

Recent phospho-proteomic analyses have revealed previously uncharacterized phosphorylation clusters that interact with T599 phosphorylation in regulating BRAF activity:

Key regulatory phosphorylation clusters:

• T401 cluster and S419 cluster in the BRAF hinge region

• These evolutionary conserved clusters are phosphorylated under multiple contexts:

  • Oncogenic RAS activation

  • Sorafenib-induced RAF dimerization

  • V600E mutation background

Functional relationship with T599:

• T401 cluster phosphorylation occurs in trans within a RAF dimer

• This phosphorylation is vemurafenib-sensitive, indicating drug-dependent conformational changes

• Substitution of Ser/Thr residues in these clusters with alanine enhances BRAF transforming potential, suggesting these sites suppress signaling output

Regulatory interplay:
Several models have been proposed for how these clusters interact with T599 phosphorylation:

• Sequential phosphorylation model: T599 phosphorylation may occur first, exposing other sites for subsequent modification

• Competitive regulation model: Phosphorylation of alternate sites may inhibit or enhance T599 phosphorylation

• Conformational control model: Different phosphorylation patterns create distinct BRAF conformational states with varying activities

These findings expand our understanding of BRAF regulation beyond the canonical T599/S602 activation loop phosphorylation, revealing a complex network of regulatory phosphorylation events that fine-tune BRAF activity in different cellular contexts .

• How can phospho-BRAF (T599) antibodies be used to investigate unusual BRAF mutations such as T599dup in different cancer types?

Phospho-BRAF (T599) antibodies offer valuable tools for investigating atypical BRAF alterations like T599dup:

T599dup mutation characteristics:

• Also referred to as T599_V600insT

• Involves duplication of threonine-599 in the protein kinase domain

• Results in increased kinase activity, increased phosphorylation of MEK and ERK

• Demonstrates transforming properties in cell culture

Research applications for phospho-BRAF (T599) antibodies:

• Diagnostic identification:

  • Use in immunohistochemistry to screen for T599dup mutations in patient samples

  • Compare phospho-T599 signal intensity patterns between T599dup and other BRAF mutations

• Drug sensitivity profiling:

  • Assess phospho-T599 levels before and after treatment with:

    • BRAF inhibitors (dabrafenib)

    • MEK inhibitors (trametinib)

    • Combination therapies

  • Correlate changes in phosphorylation with clinical responses

• Comparative studies across cancer types:
  T599dup has been observed in:

  • Melanoma (responsive to dabrafenib+trametinib)

  • Lung adenocarcinoma (responsive to dabrafenib+trametinib)

  • Colorectal cancer (resistant to FOLFOX+panitumumab)

  • Ganglioglioma (responsive to dabrafenib+trametinib)

• Mechanistic investigations:

  • Use phospho-specific antibodies in combination with structural studies to understand how T599 duplication affects the activation loop conformation

  • Investigate differences in dimerization requirements compared to V600E

Experimental approach for T599dup investigation:

• Establish cell models expressing T599dup mutation

• Assess phosphorylation status using phospho-T599 antibodies

• Compare signaling dynamics with other BRAF mutations

• Test drug responses and correlate with phosphorylation patterns

• Validate findings in patient-derived samples when available

This research is clinically important as T599dup mutations have been shown to respond to combination BRAF/MEK inhibitor therapy in multiple cancer types, suggesting phospho-T599 detection could help identify patients who might benefit from these targeted approaches .